74
Participants
Start Date
October 8, 2019
Primary Completion Date
September 9, 2026
Study Completion Date
September 9, 2026
Benralizumab
Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
Placebo
Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
Research Site, Copenhagen
Research Site, Hvidovre
Research Site, Næstved
Research Site, Odense C
Research Site, Vejle
Research Site, Aarhus N
Research Site, Aalborg
Research Site, Maspeth
Research Site, Pittsburgh
Research Site, Lund
Research Site, Winston-Salem
Research Site, New Bern
Research Site, Snellville
Research Site, Jacksonville
Research Site, Miami
Research Site, Birmingham
Research Site, Indianapolis
Research Site, Ann Arbor
Research Site, Bloomfield Hills
Research Site, Iowa City
Research Site, Rochester
Research Site, St Louis
Research Site, Kansas City
Research Site, Lewisville
Research Site, Mansfield
Research Site, Galveston
Research Site, Los Angeles
Research Site, Calgary
Research Site, Gothenburg
Research Site, Cambridge
Research Site, Headington
Research Site, Leicester
Research Site, Liverpool
Research Site, London
Research Site, Wythenshawe
Lead Sponsor
AstraZeneca
INDUSTRY